To explore the effect of combination therapy of mucosolvan and doxofylline on C-reactive protein (CRP), tumor necrosis factor (TNF), and interleukin in elderly patients with acute attack of chronic bronchitis (CBC).

74 elderly patients with acute onset of CBC admitted to our hospital from March 2015 to January 2018 were randomly divided into control group and observation group, 37 cases in each group. The control group was given routine treatment, while the observation group was given combined treatment of mucosolvan and doxofylline on the basis of routine treatment. After treatment, the improvement of lung function and the effects on CRP, TNF, and interleukin were compared between the two groups.

After treatment, CRP, TNF, and interleukin in the two groups decreased to different degrees, and those in the observation group were significantly lower than those in the control group, and the improvement of pulmonary function in the observation group was significantly better than that in the control group, with statistically significant differences between the two groups (P<0.05); the incidence of adverse reactions in the observation group was 10.8%, while that in the control group was 16.2%, without statistically significant difference between the two groups (P>0.05).

Mucosolvan combined with doxofylline can significantly improve the inflammatory response and accelerate the recovery of pulmonary function in elderly patients with acute attack of CBC. It has high medicinal safety and is worthy of clinical reference and implementation.

Mucosolvan; Doxofylline; Acute attack of chronic bronchitis